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Abstract 
Epstein-Barr virus (EBV) infection is associated with several human 
cancers. Latent membrane protein 1 (LMP-1) is one of the key viral 
proteins required for transformation of primary B cells in vitro and 
establishment of EBV latency. In this report, we show that LMP-1 is 
able to induce the expression of several interferon (IFN)-stimulated 
genes (ISGs) with antiviral properties such as 2’-5’ oligoadenylate 
synthetase (OAS), stimulated trans-acting factor of 50 kDa (STAF-
50), and ISG-15. LMP-1 inhibits vesicular stomatitis virus (VSV) 
replication at low multiplicity of infection (0.1 pfu/cell). The anti-
viral effect of LMP-1 is associated with the ability of LMP-1 to in-
duce ISGs; an LMP-1 mutant that cannot induce ISGs fails to induce 
an antiviral state. High levels of ISGs are expressed in EBV latency 
cells in which LMP-1 is expressed. EBV latency cells have antiviral 
activity that inhibits replication of superinfecting VSV. The antiviral 
activity of LMP-1 is apparently not related to IFN production in our 
experimental systems. In addition, EBV latency is responsive to vi-
ral superinfection: LMP-1 is induced and EBV latency is disrupted 
by EBV lytic replication during VSV superinfection of EBV latency 
cells. These data suggest that LMP-1 has antiviral effect, which may 
be an intrinsic part of EBV latency program to assist the establish-
ment and/or maintenance of EBV latency. 
Abbreviations: EBV, Epstein-Barr virus; CTAR, C-terminal activator region; 
IFN, interferon; HIV, human immunodeficiency virus; FBS, fetal bovine se-
rum; VSV, vesicular stomatitis virus; pfu, plaque-forming unit; moi, mul-
tiplicity of infection; LMP, latent membrane protein 1; ISG, IFN-stimulated 
genes; IRF, IFN regulatory factor; RT, reverse transcription; OAS, oligoade-
nylate synthetase; STAT, signal transducer and activator of transcription. 
Introduction 
Epstein-Barr virus (EBV)1 is a prototype of human γ-herpes-vi-
rus of increasing medical importance. EBV infection is an impor-
tant cause of lymphomas in patients with advanced HIV infection or 
AIDS, and in severely immunocompromised people, especially or-
gan transplant recipients. Also, EBV infection is associated with the 
development of nasopharyngeal carcinoma (NPC) and Burkitt’s lym-
phoma (BL) (1, 2). 
The biologic hallmark of the EBV-cell interaction is latency. 
Three types of latency have been described, each having its own dis-
tinct pattern of gene expression. Type I latency is exemplified by BL 
tumors in vivo and earlier passages of cultured cell lines derived from 
BL biopsies. EBV nuclear antigen 1 (EBNA1) protein is expressed 
in this form of latency. Type II latency is exemplified by NPC and 
Hodgkin’s disease. EBNA1, latent membrane protein 1 (LMP-1), 
LMP2A, and LMP2B proteins are expressed in type II latency. Type 
III latency is represented by lymphoblastoid cell lines (LCLs). Nine 
viral proteins are expressed, including six nuclear proteins (EBNA-
1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, and EBNA-LP) and 
three integral membrane proteins (LMP-1, LMP-2A, and LMP-2B) 
(reviewed in References 1 and 2). 
LMP-1 is an essential gene required for EBV transformation and 
establishment of latency in vitro. LMP-1 is an integral membrane 
protein with six transmembrane-spanning domains in the N terminus 
and a C-terminal domain located in the cytoplasm (2, 3). Two C-ter-
minal activator regions (CTARs) have been identified to initiate sig-
nal transduction. LMP-1 acts as a constitutively active receptor-like 
molecule that does not need the binding of a ligand (4). LMP-1 ap-
pears to be a central effector of altered cell growth, survival, adhe-
sive, and invasive potential (5–10). 
Interferons (IFNs) are cytokines with antiviral activity. The abil-
ity of IFNs to induce an antiviral state on cells is their fundamental 
property (11, 12). IFNs are produced upon the infection of cells by 
viruses. The mechanism of the transcriptional activation has been un-
der intensive investigation. One of the major players in IFN produc-
tion is IFN regulatory factor 7 (IRF-7). IRF-7 can be activated by 
phosphorylation and nuclear translocation upon viral infection and 
activated IRF-7 is partially responsible for transcriptional activation 
of IFNs (13–17). 
IFNs bind to the receptor on cell surface and activate a cascade 
of intracellular signaling pathways leading to up-regulation of more 
than 1000 IFN-stimulated genes (ISGs) within the cell. STAT-1 is a 
major component of signal transducers for IFN for ISG production 
(reviewed in References 11 and 12). 
ISGs have multiple functions. The induction of antiviral ISGs 
confers the cells with antiviral activity. The antiviral functions of 
several ISGs are well understood. The IFN-inducible 2’-5’ oligoad-
enylate synthetase (OAS) catalyzes the synthesis of oligoadenylates 
of the general structure ppp(A2’p)nA, commonly abbreviated 2–5A. 
RNase L, a latent endoribonuclease, becomes activated by binding 
2–5A oligoadenylates. Activated RNase L catalyzes the extensive 
cleavage of single-stranded RNA of both viral and cellular origins, 
including rRNA (11, 12). Overexpression of OAS alone is sufficient 
to block the replication of virus in the absence of any other IFN-in-
ducible proteins (18). 
Other well established antiviral ISGs are dsRNA-activated protein 
kinase, PKR, and myxovirus resistance-1 (Mx1 for mice and MxA for 
humans) genes. The antiviral effect of PKR is due to its phosphoryla-
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tion of the alpha subunit of initiation factor (eIF-2α). This phosphor-
ylation results in rapid inhibition of translation. Mx proteins interfere 
with the growth of influenza and other negative strand RNA viruses 
at the level of viral transcription and at other steps (11, 12). 
Many ISGs are poorly characterized, and some of these are very 
likely to possess antiviral activity. Stimulated trans-acting factor of 
50 kDa (STAF-50) is a member of the ring finger family, now col-
lectively called TRIM for proteins containing a tripartite motif (19). 
STAF-50 has a significant inhibition of the retroviral infections (20). 
It is also a target and down-regulated in human papillomavirus-in-
fected cells (21). ISG-15 is involved in the repression of human im-
munodeficiency virus (HIV) replication by IFN (22). Also, expres-
sion of ISG-15 is correlated with antiviral responses (23, 24). Clearly, 
the enormous selective pressures imposed by viral infection have re-
sulted in a rich and diverse set of antiviral pathways. 
Previously, we have shown that LMP-1 induces the expression 
of IRF-7 and STAT-1; both of which are ISGs and involved in the 
antiviral response of cells (25, 26). In this report, we extend our 
earlier discovery and show that LMP-1 induces several other antivi-
ral ISGs implicated in cellular antiviral responses. We further show 
that LMP-1 possesses antiviral activity, and EBV latency cells in-
hibit the replication of superinfecting viruses. We propose that the 
antiviral effect of LMP-1 may be an intrinsic part of EBV latency, 
which may be used to assist the maintenance and/or establishment 
of EBV latency. 
Materials and Methods 
Plasmids, Antibodies, and Viruses—Expression plasmids of LMP-1 and 
mutant (LMP-DM) were described previously (27). ISG-15 monoclonal an-
tibody from Dr. Bordin; and MxA antibody from Dr. Mark A. McNiven (28). 
Tubulin was purchased from Sigma. STAT-1 antibody (sc-417, sc-591) was 
from Santa Cruz Biotechnology. Phospho-Tyr-701 STAT-1 antibody (06-657) 
was from Upstate Biotechnology. LMP-1 Ab (CS1-4) was purchased from 
Dako. Stock of VSV (Indiana serotype) was prepared and titrated in BHK-
21 cells. A mouse polyclonal antibody raised against purified VSV was used 
for detection of VSV proteins in infected cells. Sendai virus stock was pur-
chased from Spafas, Inc. Anti-sendai virus antibody was purchased from US 
Biologicals, Inc. Recombinant human IFN-α2a was purchased from Hoffman-
La Roche Inc. 
Cell Culture, Transient Transfection, and Isolation of Transfected Cells—
DG75 is an EBV-negative Burkitt’s lymphoma cell line (29). BL41 is EBV-
negative BL lines, BL41-EBV was generated by in vitro infection with EBV 
B95-8 strain (30). SavI, Daudi, P3HR-1, and Jijoye are all EBV-positive BL 
lines (31–33). These cells were maintained in RPMI 1640 plus 10% fetal bo-
vine serum (FBS). Baby hamster kidney (BHK-21) cells are maintained in 
MEM containing 5% FBS. 293 are human fibroblasts and are maintained in 
Dulbecco’s modified Eagle’s medium plus 10% FBS. Electroporation was 
used for transfection of the B cells as described previously (26, 27, 34). En-
richment for CD-4-positive cells was performed with the use of anti-CD-4-an-
tibody conjugated to magnetic beads according to the manufacturer’s recom-
mendation (Dynal, Inc.). DG75 cells were transfected with CD-4 expression 
and other plasmids. One day after the transfection, the cells were used for iso-
lation of CD-4-positive cells with the use of Dynabeads CD4 (Dynal Inc.) The 
transfected cells were incubated with Dynabeads CD4 at 72 µl of beads/107 
cells for 20–30 min at 4 °C with gentle rotation. CD4-positive cells were iso-
lated by placing the test tube in a magnetic separation device (Dynal magnet). 
The supernatant were discarded while the CD4-positive cells are attached to 
the wall of the test tube. The CD4-positive cells were washed 4–5 times in 
phosphate-buffered saline plus 2% FBS, and resuspended in 100 µl RPMI 
1640 plus 1% FBS. Cells were detached from the Dynabeads CD4 by incu-
bate for 45–60 min at room temperature with 10 µl of DETACHaBEAD. The 
detached beads were removed by using a magnetic separation device. The 
released cells were washed 2–3 times with 500 µl of RPMI 1640 plus 10% 
FBS, and resuspended in RPMI 1640 plus 10% FBS at 5 x 105 cells/ml. The 
isolated cells were used to extract total RNAs or prepare cell lysates immedi-
ately, or recovered overnight before infection by viruses. 
Western Blot Analysis with Enhanced Chemiluminescence (ECL)— Sep-
aration of proteins on SDS-PAGE was carried out following standard proto-
col. After the proteins were transferred to a nitrocellulose or Immobilon mem-
brane, the membrane was blocked with 5% nonfat dry milk in TBST (50 mM 
Tris-HCl pH 7.5, 200 mM NaCl, 0.05% Tween-20) at room temperature for 
10 min. It was then washed briefly with water, and incubated with the pri-
mary antibody in 5% milk in TBST for 1 h at room temperature, or overnight 
at 4 °C. After washing with TBST three times (10 min each), the membrane 
was incubated with the secondary antibody at room temperature for 1 h. It 
was then washed three times with TBST, treated with ECL detection reagents 
(Amersham Biosciences), and exposed to Kodak XAR-5 film. 
RNA Extraction and RNase Protection Assays (RPA)—Total RNA was 
isolated from cells using the RNeasy Total RNA Isolation Kit (Qiagen, Va-
lencia, CA). RPA was performed with total RNA using the RNase Protection 
Assay Kit II (Ambion, Houston, TX). The GAPDH probe was from US Bio-
chemicals, Inc. The probe for STAF-50 was made from the PCR product am-
plified using the two primers from STAF-50: 5’-GGGGTACCGACGTCAT-
GAAAAGGAGTG-3’ and 5’-GGATTTGAATTCTTAAATGTG-3’. The PCR 
product was then cloned into pcDNA3 vector. The probe for OAS was a gift 
from Dr. Teresa Compton. 
Plaque Assays—BHK-21 cells were grown in 12- or 6-well plates to 90% 
confluency. Cells were infected in duplicates with serial 10-fold dilutions of 
cell culture supernatants. After an initial adsorption of 45 min, the inoculum 
was aspirated out, and cells were washed two times with medium. Cells were 
then overlaid with 1.5 ml of MEM containing 2% FBS and 0.75% low melt-
ing point agarose (Invitrogen) and incubated for 15–18 h. After the incubation 
period, cells were fixed with 1 ml of 2% glutaraldehyde in phosphate-buffered 
saline for 1 h at room temperature. The agarose plugs were then removed, and 
cells were stained for 10–15 min with 0.01% crystal violet in 30% methanol. 
Cells were then washed with water and air-dried. The plaques were counted, 
and titers determined by taking the average. 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)—Total 
RNA was isolated from samples by using RNAeasy kit (Qiagen). The RNA 
samples were treated with DNase I at 37 °C for 30 min. The primers used 
in this experiment are as follows. For all IFN-α genes, the consensus prim-
ers for all IFN-α subtypes were used. IFNA5: 5’-AGA ATC TCT CCT TTC 
TCC TG-3’ and IFNA3: 5’-TCT GAC AAC CTC CCA GGC AC-3’; For IFN-
α1: IFNA15, 5’-GCA ATA TCT ACG ATG GCC TC-3’ and IFNA13, 5’-CAG 
AAT TTG TCT AGG AGG TC-3’; For actin gene: Actin1, 5’-TTC TAC AAT 
GAG CTG CGT GT-3’ and Actin 2, 5’-GCC AGA CAG CAC TGT GTT GG-
3’. Positive controls were RNAs from either 293 cells transfected with con-
stitutively active form of IRF-7 (IRF7Δ247–467) (16) or 293 cells infected 
with 200 hemagglutinin units of Sendai virus. Both positive controls pro-
duced similar results. RT-PCR was performed with SuperScriptTM One-Step 
RT-PCR with Platinum® Taq (Invitrogen) following manufacturer’s protocol. 
One set of primers for IFN and actin primers were mixed for the detection of 
IFN and actin simultaneously. 
Statistical Analyses—Mean values ± S.D. were calculated by Micro-
soft Excel program. The significance between two groups was calculated by 
Mann-Whitney U Test with the use of the Statistca 6.0 program. 
Results 
LMP-1 Selectively Stimulates the Expression of Antiviral ISGs—
We have previously shown that LMP-1 induces IRF-7, STAT-1, and 
STAT-2 in human B cells (25, 26). In addition, EBV infection in-
duces expression of ISGs (35). All these available data suggest that 
EBV, or LMP-1 in particular, may have the ability to induce other 
ISGs. Because of the role of STAT-1 and IRF-7 in cellular antiviral 
responses, we examined whether LMP-1 can induce other known 
antiviral ISG genes. DG75 cells, which are EBV-negative Burkitt’s 
lymphoma cells, were used for the test because of the transfection 
efficiency. LMP-1 has two critical domains (CTAR-1 and CTAR-2) 
for its signaling. Point mutations at the CTAR-1 that change the PX-
QXT motif into AXAXT will destroy the signaling pathways initi-
ated from CTAR1. The tyrosines (Y) in the last three amino acids of 
LMP-1 (YYD) have been shown to play an important role in the sig-
naling pathway of CTAR2; the mutations of YYD abolish the activa-
tion of NF-κB and AP-1. LMP-DM has point mutations at the criti-
cal residues in both CTAR-1 and -2 (27). LMP-1 or LMP-DM, was 
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transfected into DG75 cells and the transfected cells were enriched 
by CD4 selection (see “Materials and Methods” for detail). West-
ern blotting or RNase protection assays (RPAs) were used for detec-
tion of the expression of target genes based on availability of probes 
and specific antibodies. As shown in Figure 1A, LMP-1 induced the 
RNA expression of OAS and STAF-50. In addition, LMP-1 caused 
a marked increase in ISG-15 protein levels (Figure 1B). However, 
LMP-DM failed to induce the expression of OAS, STAF-50, and 
ISG15. The results indicate that LMP-1 induced expression of the 
three ISGs, and the two CTARs of LMP-1 were required for the in-
duction. However, LMP-1 could not induce the expression of PKR, 
IRF-1, or MxA proteins in DG75 cells (data not shown). Thus, these 
data indicate that LMP-1 selectively induces antiviral ISGs. 
LMP-1 Inhibits VSV Protein Expression—One of the common 
functions for OAS, IRF-7, STAT-1, STAF-50, and ISG-15 proteins is 
their potential roles in the establishment of antiviral state in a cell (for 
a review, see References 11 and 12). It is possible that LMP-1 might 
have an antiviral effect via the induction of these ISGs. To test the hy-
pothesis, we first examined whether viral gene expression was affected 
in LMP-1-expressing cells. LMP-1 expression plasmid or its vector 
(pcDNA3) was transfected into DG75 cells, and the transfected cells 
were selected for vesicular stomatitis virus (VSV) infection for 8–10 
h. The reason to use VSV is mainly because VSV infects human B 
cells efficiently. Figure 2 shows the comparison between LMP-1-ex-
pressing cells and vector control cells in their abilities to support VSV 
gene expression. At high multiplicity of infection (moi), LMP-1 could 
not inhibit the expression of VSV proteins effectively (lanes 3 and 
4). However at lower moi (0.1 pfu/cell), LMP-1 significantly inhib-
ited VSV protein expression (lanes 5 and 6). Also, IFN repressed VSV 
protein expression as expected (data not shown). In addition, second 
non-related virus, sendai virus, was used to infect LMP-1-expressing 
cells. LMP-1 also inhibited the sendai virus gene expression (data not 
shown). Thus, LMP-1 was able to repress VSV gene expression and 
the inhibitory effect was not a virus-specific phenomenon. 
 LMP-1-mediated Inhibition of VSV Replication Is Associated 
with ISG Induction—In order to examine the relationship between the 
inhibition of viral protein expression and induction of ISGs by LMP-
1, we tested if LMP-DM mutant that failed to induce any ISGs could 
inhibit VSV protein expression. As shown in Figure 3A, LMP-1, but 
not LMP-DM, inhibited VSV protein expression. These data suggest 
that LMP-1 is able to inhibit VSV gene expression and the inhibition 
is associated with the induction of antiviral ISGs. 
  In addition to viral protein expression, we also performed plaque 
assays to detect VSV production in the media. In agreement with pro-
tein expression data (Figs. 2 and 3A), LMP-1 was able to inhibit the 
production of VSV, up to 100-fold (Figure 3B). Thus, data from both 
viral protein expression and virus production suggested that LMP-
1 inhibited the replication of VSV. Furthermore, marginal inhibition 
of VSV production was observed with the LMP-DM mutant (Figure 
3B). Because LMP-DM failed to induce any ISGs tested, these data 
suggest that induction of ISGs is an important step in the establish-
ment of antiviral state by LMP-1. 
Cells Harboring EBV Inhibited VSV Replication—It is important 
to determine whether LMP-1 in native environment in EBV latency 
cells also induces the expression of ISGs and inhibits viral replica-
Figure 1. LMP-1 stimulates the expression of ISGs. A, LMP-1 induces expression of OAS and STAF-50 RNA. Total RNAs (5 µg) from DG75 cells transfected 
with pcDNA3, LMP-1, or LMP-DM expression plasmids were used for RPA. OAS plus GAPDH, or STAF-50 plus GAPDH probes were used. Yeast RNA was 
used as negative control. Specific protections of OAS, STAF-50, and GAPDH RNAs are indicated. The relative level of STAF-50 RNA (STAF-50/GAPDH) in-
duced by LMP-1 is 3.8-fold calculated from three independent experiments (two of which are shown). B, LMP-1 induces expression of ISG-15 protein. Lysates 
from pcDNA3, LMP-1, or LMP-DM expression plasmid transfected and enriched DG75 cells were used for Western blot analysis with tubulin, ISG15 as well as 
LMP-1 antibodies. The identity of proteins is as shown.
Figure 2. LMP-1 inhibits VSV protein expression. DG75 cells were trans-
fected with pcDNA3 (vector, lanes 1, 3, 5, and 7) or LMP-1 expression plas-
mids (lanes 2, 4, 6, and 8). The transfected cells were isolated and infected 
with VSV for 8–10 h. Cell lysates were used for Western blot analysis using 
VSV-specific antibodies. The same membrane was stripped and used with dif-
ferent antibodies. The multiplicity of infection is shown on the top. The iden-
tity of the proteins is as shown. * =  residual VSV proteins.
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tion. BL41, a Burkitt lymphoma line, and its EBV-infected deriva-
tive, BL41-EBV, were used to investigate the issue. The two cell lines 
have the identical genetic backgrounds and have been shown to be a 
good pair to analyze the effect of EBV on the cellular gene expres-
sion (35). BL41-EBV is a type III latency cell line in which LMP-1 is 
expressed (Figure 4C). Total RNA or cell lysates were prepared from 
these cells. RPA experiments demonstrated that expression of OAS 
and STAF-50 were increased in cells harboring EBV (Figure 4A). 
Also, Western blotting demonstrated a clear increase in both ISG15 
and STAT-1 proteins expression after EBV infection (Figure 4B). In 
addition, IRF-7 is also highly expressed in BL41-EBV (26). These 
data suggest that the induction of antiviral ISGs is a consequence of 
the establishment of EBV latency in human B cells. 
Next, we examined the viral replication efficiencies in BL41 and 
BL41-EBV cell lines. As shown in Figure 4C, VSV protein expres-
sion was significantly lower in BL41-EBV in which LMP-1 is ex-
pressed. Also, VSV viral productions were consistently lower in 
the BL41-EBV cells (Figure 4D). Statistically, the differences in vi-
ral yields between BL41 and BL41-EBV are highly significant (p < 
0.01). The modest inhibition of viral replication may be caused by 
other EBV latent gene(s) has ability to neutralize the effect of LMP-
1. These data suggest that EBV latency cells have the ability to sup-
press viral replication, and LMP-1 in native environments may be ca-
pable of inhibiting viral replication. 
IFNs Were Not Involved in LMP-1-mediated Antiviral Effect in 
DG75 Cells—One possible mechanism for LMP-1 to induce the ex-
pression of ISGs and antiviral state is indirectly via the induction of 
IFNs. The possibility was examined by several approaches in DG75 
cells in which the induction of ISGs and antiviral effect of LMP-1 
were observed (Figs. 1, 2, 3). First, we examined if LMP-1 induced 
the synthesis of IFN RNAs in LMP-1 expressing cells. RT-PCR was 
carried out in LMP-1-transfected cells with IFN and actin primers. 
Two sets of IFN primers were used in this assay. One was designed 
to detect mRNAs of all IFN-α subtypes (especially IFN-α1, -2, -4, -
7, -10, -13, and -14) and another to detect only IFN-α1 mRNA, the 
most abundant IFN-α1 subtype (36, 37). As shown in Figure 5A, RT-
PCR results suggested that all IFN-α subtypes and IFN-α1 were not 
synthesized in greater amount in LMP-1-expressing cells; suggesting 
that LMP-1 might not be able to induce the expression of IFN-α. 
Figure 3. LMP-1 inhibits VSV virus production. A, LMP-1 mutant fails to inhibit VSV protein expression. DG75 cells were transfected with pcDNA3, LMP-1, 
or LMP-DM expression plasmids. The transfected cells were isolated and infected with VSV at 0.1 moi for 8–10 h. Cell lysates were used for Western blot analy-
sis using VSV-specific antibodies. The same lysates were used for detection of tubulin and LMP-1 antibodies. The identity of proteins is as shown. B, LMP-1 in-
hibits VSV production. DG75 cells transfected with pcDNA3, LMP-1, or LMP-DM were infected by VSV at 0.1 moi for 12 h. VSV production was measured by 
plaque assay. The virus yields are as shown in logarithm units. The results represent an average of three independent experiments. Error bars represent S.D.
Figure 4. EBV latency has antiviral property. A, RNA expression of OAS 
and STAF-50 are associated with EBV type III latency. Total RNAs (5 µg) 
from BL41 or its EBV-infected counterpart BL41-EBV were used for RPA 
with mixed probes of OAS, STAF-50, and GAPDH. Yeast RNA was used as 
negative control. Specific protections of OAS, STAF-50, and GAPDH RNAs 
are indicated. B, expression of ISG15 and STAT-1 proteins are associated with 
EBV type III latency. Lysates from BL41 and BL41-EBV were used for West-
ern blot analysis with tubulin, ISG15 as well as STAT-1 antibodies. The iden-
tity of proteins is as shown. C, VSV protein expression is inhibited in EBV la-
tency. BL41 and BL41-EBV were infected with VSV at 0.1 moi for 8–10 h. 
Cell lysates were used for Western blot analysis using VSV, LMP-1, and tu-
bulin antibodies. The identity of proteins is as shown. D, VSV production is 
inhibited in EBV latency. VSV (0.1 moi) was used to infect BL41 and BL41-
EBV. Relative VSV productions in BL41 and BL-41-EBV after 12 h post-in-
fection are shown. The significance in VSV yields between BL41 and BL41-
EBV was calculated by Mann Whitney U Test with the use of the Statistca 6.0 
program. p value and sample numbers (n) are shown.
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Our data in Figure 5A could not rule out the possibility that LMP-
1 might induce a rare member of IFN family, which might be respon-
sible for the induction of ISG. We reasoned if LMP-1 induced the 
expression of biologically active IFNs, STAT-1 would be activated 
by these IFNs. It is well known that the phosphorylation at the crit-
ical Tyr-701 residue of STAT-1 is a crucial event for its function in 
IFN signaling. We tested the activation status of STAT-1 by the use of 
specific antibodies for phospho-STAT-1 (Tyr-701) in LMP-1-express-
ing cells. As shown in Figure 5B, STAT-1 was not phosphorylated, or 
very marginally activated, at the critical Tyr-701 residue in LMP-1-
positive cells. Also, STAT-1 in LMP-1-positive EBV latency cells is 
not activated (25). Thus, the data suggest that LMP-1 did not produce 
significant amount of biologically active IFNs that were capable of 
activating STAT-1. 
If LMP-1 could induce IFNs and/or other soluble antiviral pro-
teins, then the media from LMP-1-expressing cells would be able 
to induce an antiviral state on other cells. To test this possibility, the 
conditional media from LMP-1-expressing cells were used to treat 
DG75 cells overnight and these cells were then infected with VSV. 
As shown in Figure 5C, the conditional media failed to inhibit VSV 
replication in DG75 cells, but treatment of IFN marginally interfered 
with VSV production. The results suggest the media from LMP-1-ex-
pressing cells could not induce an antiviral state (Figure 5C). Thus, 
LMP-1-mediated antiviral response is not related to secreted IFNs or 
other antiviral factors. 
VSV Production Is Insensitive to IFN in DG75 Cells—It is inter-
esting that IFN-treated DG75 cells were still supporting decent VSV 
production (Figure 5C). We suspected that DG75 cells might insen-
sitive to IFN-mediated inhibition of VSV production. Both 293 and 
DG75 cells were treated with the same IFN for same time, and in-
fected with VSV. As shown in Figure 5D, whereas IFN significantly 
inhibited VSV production in 293 cells, IFN could not produce a sig-
nificant inhibition of VSV production in DG75 cells. Thus, VSV pro-
duction is insensitive to IFN treatment in DG75 cells. It is of note 
that DG75 cells are responsive to IFN treatment: IRF-7, ISG15, and 
PKR were increased upon treatment of IFNs (data not shown). Be-
cause our data show that LMP-1 significantly inhibit VSV produc-
tion in the same cells (Figure 3), these results strongly suggest that 
LMP-1-mediated antiviral response in DG 75 cells is irrelevant to 
IFN production. 
Viral Infection Induced the Expression of LMP-1—Because the 
LMP-1 promoter region has an ISRE-like element and is responsive 
Figure 5. IFNs were not involved in LMP-1-mediated antiviral effect in DG75 cells. A, LMP-1 did not induce great amount of IFNs. IFN-α mRNA levels 
were analyzed in cells expressing LMP-1 and its vector controls. RNA from 293 cells transfected with IRF7Δ247–467 was used as positive control. One-step RT-
PCRs were performed with consensus IFN-α and actin primers or specific IFN-α1 primers plus actin, respectively. The PCR products were separated on 8% poly-
acrylamide gel. The identity of the RT-PCR products is as shown. B, LMP-1 did not induce the phosphorylation of STAT-1 at a critical tyrosine residue. Western 
blot with phosphospecific STAT-1 antibody was first performed. The membranes were then stripped and antibodies against intact STAT-1, LMP-1, as well as tu-
bulin were used to determine the expression of total STAT-1 and others. The positive control was lysates from Jijoye cells that had been treated with IFN-α  for 
30 min. The identity of proteins is as shown. C, media from LMP-1-expressing cells were unable to induce an antiviral state. Media from LMP-1-expressing cells 
were obtained by removal of cells by centrifuging. The media were mixed with fresh DG75 cells at 1:1 ratio for 12 h before infection of VSV at 0.1 moi. The pos-
itive control was IFN-treated DG75 cells. The relative VSV production is as shown. D, VSV production is insensitive to IFN in DG75 cells. 293 and DG75 cells 
were treated with IFN overnight, and then infected with VSV (0.1 moi) for 12 h. The relative VSV production is as shown. Squares, DG75; triangles, 293 cells.
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to IRF-7 (38), we reasoned that LMP-1 might be inducible by viral 
superinfection in EBV latency cells. P3HR1 is a Burkitts’ lymphoma 
line that lacks the EBNA-2 gene and a portion of EBNA-LP (31). As 
a result of the deletion, P3HR1 cells do not express EBNA-2, and 
consequently because EBNA-2 trans-activates the LMP-1 promoter 
(39–42), express a very low level of LMP-1. As shown in Figure 6A, 
VSV infection induced expression of LMP-1 protein in P3HR1 cells. 
Similar results were obtained in Daudi cells and sendai virus also in-
duced the expression of LMP-1 (data not shown). However, expres-
sion of LMP-1 RNA was sensitive to protein synthesis inhibitor, cy-
cloheximide (data not shown). In addition, VSV marginally activated 
LMP-1 promoter reporter constructs in EBV-negative cells (data not 
shown). Thus, these data suggest that VSV infection triggers the syn-
thesis of LMP-1, but de novo protein synthesis of viral or cellular 
factor(s) is required for the induction. 
Viral Infection Induced Lytic Replication of EBV—To test what 
may happen in EBV latency cells super-infected with other viruses, 
we examined if VSV could disrupt EBV latency by inducing lytic 
replication of EBV. We used EBV EA-D (BMRF-1) expression as a 
marker for lytic replication. The essential function of EA-D in EBV 
lytic replication has been well established and using EA-D as an in-
dicator of lytic replication has been appreciated in the field for years 
(43–49). As shown in Figure 6B, VSV infection induced expression 
of EA-D in two latency cell lines. Multiple bands for EA-D are a 
common phenomenon due to the phosphorylation (48, 49). Sendai vi-
rus infection also induced the expression of EA-D (data not shown). 
These data strongly suggest that viral superinfection might disrupt 
EBV latency by inducing EBV lytic replication. 
Discussion 
It is well established that OAS is a major component of cellu-
lar antiviral responses (11, 12); IRF-7 is a key factor responsible for 
IFN production upon vial infection (13–16); and STAT-1 is an essen-
tial transducer for IFN signal transduction (50, 51). These genes are 
essential for cells to establish an antiviral state and play important 
roles in viral pathogenesis (11, 12). In this report, we have shown 
that LMP-1 induces several antiviral ISGs including OAS and pro-
vided evidence that LMP-1 has antiviral effect. In addition, we dem-
onstrate that EBV type III latency cells, in which LMP-1 is expressed 
at physiological levels, have the capability to induce ISG productions 
and inhibit superinfecting virus replication. 
The induction of ISGs may be the molecular bases for the anti-
viral effect of LMP-1. Some ISGs, such as OAS, when expressed at 
high levels are sufficient to repress viral replication in the absence 
of other ISGs (18). Overexpression of IRF-7 alone is also able to in-
hibit VSV replication as expected (data not shown). The inhibition is 
apparently related to the induction of IFN because an IRF-7 mutant 
that cannot induce IFN production failed to inhibit the replication of 
VSV (data not shown). In addition, LMP-1 may modulate some anti-
viral protein activity. The transmembrane domain of LMP-1 has been 
shown to initiate phosphorylation of eIF-2α, which would result in 
inhibition of viral replication (11, 12, 52). Thus, through induction 
of antiviral ISGs and modulation of existing protein activities, LMP-
1 may obtain the ability to suppress viral replications. In support of 
such as a notion, LMP-DM, which failed to induce the expression of 
several ISGs, was unable to induce antiviral state (Figure 3). How-
ever, the major contributor(s) in LMP-1-mediated antiviral response 
is currently unknown. 
The induction of antiviral OAS, STAF-50, STAT-1, and ISG-15 
is associated with EBV latency and LMP-1 expression (Figure 4). In 
addition, IRF-7 is also highly expressed in EBV latency (26, 53), and 
induction of other ISGs in EBV latency has been reported (35). These 
results suggest that the induction of ISGs is likely to be a property 
of EBV latency and, based on our results, related to the expression 
of LMP-1. Furthermore, EBV latency cells do have antiviral effect 
(Figure 4, C and D). The antiviral effect is modest but statistically 
highly significant (p < 0.01). The modest antiviral effect in EBV la-
tency cells might be due to other viral factor(s) diminishing the effect 
of LMP-1. EBNA-2 has been shown to block the function of ISGs 
(54). Also, other herpesviruses, such as herpes simplex virus 1 (HSV-
1) and cytomegalovirus (CMV), initiate an ISG production and use 
other viral genes to block antiviral effects (55–62). 
Because ISG induction is a major outcome with IFN treatment, 
one possibility is that the activation of ISGs by LMP-1 is indirect 
via the induction of IFNs. However, it is unlikely that IFN is a major 
player in the process. First, RT-PCR results suggest that IFNs were 
not synthesized in great amount in LMP-1-expressing cells (Figure 
5A). Second, LMP-1-induced expression of STAT-1 was not phos-
phorylated at the tyrosine residue 701, the phosphorylation of which 
is critical for IFN signaling (Figure 5B). Third, the media from LMP-
1-expressing cells could not induce an antiviral state on other cells 
(Figure 5C). Fourth, DG75 cells are insensitive to IFN-induced in-
hibition of VSV production (Figure 5D). Fifth, LMP-1 selectively 
induces ISGs (Figure 1), and LMP-1 can induce phosphorylation 
of eIF-2α, apparently not through PKR (52). Sixth, the induction of 
ISGs in EBV latency was shown to be independent of IFNs (35). Sev-
enth and finally, IFN was not involved in the induction of ISGs upon 
Figure 6. Responses of EBV latency cells to VSV superinfection. A, superinfection of EBV latency cells induces LMP-1 expression. VSV was used to infect 
P3HR1 cells for 16–24 h. Western blot with LMP-1 and tubulin antibodies was performed first. The membrane was then stripped and probed with VSV anti-
body. The identity of proteins is as shown. Lane 1, uninfected cells; lanes 2 and 3, cells infected with VSV at 0.1 or 1 moi, respectively. B, VSV infection induces 
EA-D expression. VSV was used to infect Sav I and Jijoye cells for 24 h. Cell lysates were separated by SDS-PAGE. Western blot with EA-D antibody was per-
formed first. The membrane was then stripped and probed with tubulin antibody. The positive controls are EBV-BZLF1 transfected cells. The identity of proteins 
is as shown.
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infection by other herpesviruses (35, 60, 61, 63, 64). Thus, based on 
our data presented here and previously published results, it is likely 
that the observed antiviral function is a direct effect of LMP-1, and 
IFN may not be a major factor in the process at least in DG75 cells. 
LMP-1 may use multiple mechanisms for the induction of ISGs. 
Notably, LMP-1 induces both STAT-1 and -2 in Akata cells; how-
ever, LMP-1 cannot induce IRF-7 in the same line (25, 26). Further-
more, the detailed domain requirement for the induction of IRF-7 and 
STAT-1 are different (25, 27). Thus, inductions of IRF-7 and STAT-
1 by LMP-1 are obviously via different mechanisms. We also tested 
the role of LMP-1 in the activation of IRF family members. Specifi-
cally, LMP-1 could not induce the expression of IRF-1 and IRF-3 in 
DG75 cells. In addition, LMP-1 failed to activate IRF-3 based on the 
subcellular localization (data not shown). Thus, IRF-7, which can be 
induced and activated by LMP-1, might be the most relevant mem-
ber in IRF family to induce ISGs. All ISG promoter regions have one 
or more ISREs (11, 12). Activated IRF-7 might be able to selectively 
induce the expression of ISGs based on the binding affinities to var-
ious ISREs and other factors. The expression of Tap-2, another ISG, 
was shown to be regulated by IRF-7 (34). Although LMP-1 cannot 
activate STAT-1 protein at the critical tyrosine residue, but because 
STAT-1 can also induce ISGs under non-activated state (65), we sus-
pect that STAT-1 may also be involved in the induction of certain 
ISGs in the absence of IFN. 
EBV has both latency and lytic replication in its life cycle. EBV 
latency can be disrupted by lytic replication, which can be induced 
by many chemical or physiological factors. In this report, we have 
shown that the infection of EBV latency cells by VSV or Sendai virus 
induced EBV lytic replication (Figure 6 and data not shown). In ret-
rospect, EBV superinfected EBV latency cells induced lytic replica-
tion (66–69). In addition, HHV-6 and CMV infection of EBV latency 
cells would also lead to lytic replication of EBV (70–72). These re-
ports plus our data in Figure 6 have suggested a general conclusion 
that a viral superinfection of EBV latency cells would lead to lytic 
replication of EBV and the disruption of EBV latency program. 
EBV has several latencies with various expression levels of LMP-
1. A superinfection of EBV latent cells by a foreign virus may trigger 
the synthesis of LMP-1 (Figure 6A). Interestingly, infection of EBV 
latency cells by EBV itself or HHV-6 also induced the expression of 
LMP-1 (73–75). These data suggest that LMP-1 induction may be a 
common response of EBV latency cells to superinfection, and the an-
tiviral effect of LMP-1 may be a general property of all EBV laten-
cies, regardless of the original LMP-1 status. Based on facts that in-
duction of LMP-1 RNA was sensitive to protein synthesis inhibitor 
(data not shown), and fact the LMP-1 is expressed in lytic replication 
cycle (73, 76, 77), it is likely the induction of EBV lytic replication 
has resulted in the synthesis of LMP-1. Because LMP-1 is able to in-
hibit EBV lytic replication via at least two mechanisms (78, 79), the 
antiviral function of LMP-1 might also be functioning in lytic repli-
cation cycle by inhibiting EBV lytic replication. 
Finally, it is of note that an antiviral stage can be induced by 
many different stimuli; such as bacterial infection and environmental 
stresses (11, 12). Thus, the establishment of an antiviral stage is not 
solely for the protection of the cells from super infection, but a gen-
eral response to protect the cells in harsh environments. The antiviral 
function of LMP-1 may help EBV latency cells to cope with a variety 
of foreign attacks as well as changes in cellular environments by pro-
moting EBV latency as well as blocking EBV lytic replication. 
In summary, our results indicate that LMP-1 induces antiviral 
ISGs selectively, and has an antiviral effect. LMP-1-mediated antivi-
ral effect may be an intrinsic part of EBV latency program, and may 
assist the establishment and/or maintenance of EBV latency. 
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